All News
Filter News
Found 3,313 articles
-
Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases
1/17/2024
Tr1X, Inc. announced its emergence from stealth with a $75 million Series A financing to bring universal allogeneic regulatory T and CAR-Treg cell therapies to the clinic to treat and potentially cure autoimmune and inflammatory diseases.
-
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
1/17/2024
INVO and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024.
-
Following the J.P. Morgan Healthcare Conference and other parallel meetings in San Francisco, it’s time to reflect on some of the significant deals secured last week.
-
Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
1/16/2024
Mirum Pharmaceuticals, Inc., announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical development, clinical operations, and safety programs for Mirum’s pipeline of programs addressing rare diseases.
-
Dropping the potential Cytokinetics buy runs contrary to Novartis’ recent dealmaking frenzy, which included the acquisition of Calypso and three research collaborations.
-
Autonomix Medical, Inc. Completes Formation of Engineering Development Team and Provides Project Update
1/11/2024
Autonomix Medical, Inc. announced the completion of its engineering development team formation and provided an engineering update.
-
Clarivate’s latest Drug to Watch list highlights new modalities shaping drug development, including gene editing and artificial intelligence.
-
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
1/9/2024
Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of TIVDAK® (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.
-
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
1/9/2024
Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of TIVDAK® (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.
-
NeuroTrauma Sciences Appoints William Fricker, CPA, MBA, as Chief Financial Officer
1/9/2024
NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing neuroprotective therapeutics for treating central nervous system (CNS) injuries including stroke and traumatic brain injury, today announced the appointment of William Fricker, CPA, MBA, to Chief Financial Officer, effective immediately.
-
The pharmaceutical giant will pay $28 a share to acquire Ambrx’s pipeline of ADCs, particularly its lead candidate for prostate cancer.
-
Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board
1/8/2024
f, which is building the leading platform for cell programming and biosecurity, announced the formation of its new Biopharma Advisory Board.
-
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
1/8/2024
Zura Bio Limited announced the appointments of Robert Lisicki as President and Chief Operating Officer, and Kiran Nistala, MBBS, PhD, as Executive Vice President Development and Chief Medical Officer, to the Executive Leadership Team.
-
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
1/8/2024
Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired.
-
Ambrx Announces Sale to Johnson & Johnson
1/8/2024
Ambrx Biopharma, Inc., or Ambrx, announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx’s closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion.
-
Merit Medical Announces Projected Preliminary Unaudited Revenue for the Year Ended December 31, 2023 and Plans to Announce Fourth Quarter and Year End 2023 Results and Issue Fiscal Year 2024 Guidance on February 28, 2024
1/8/2024
Merit Medical Systems, Inc., a leading global manufacturer and marketer of healthcare technology, announced projected preliminary unaudited revenue in the range of approximately $1.255 to $1.259 billion for the year ended December 31, 2023, a projected increase of approximately 9.0% to 9.4% compared to revenue reported for the year ended December 31, 2022.
-
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
1/8/2024
Essential Pharma announces that it has completed the acquisition of European rights to Colobreathe® from Teva Laboratories UK Limited.
-
Twist Bioscience Appoints Adam Laponis as Chief Financial Officer
1/5/2024
Twist Bioscience Corporation today announced the appointment of Adam Laponis as chief financial officer.
-
Align Technology Completes Acquisition of Cubicure, a Pioneer of Direct 3D Printing Solutions for Polymer Additive Manufacturing
1/3/2024
Align Technology, Inc. announced that it has completed the acquisition of privately-held Cubicure GmbH, a pioneer in direct 3D printing solutions for polymer additive manufacturing that develops, produces, and distributes innovative materials, equipment, and processes for novel 3D printing solutions.
-
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
12/29/2023
LumiraDx Limited, a next generation point of care diagnostics company, announced the appointment of joint administrators for two of its subsidiaries.